Scrip
Repros agrees debt settlement after Proellex clinical hold
03 November 2009
Christopher Spillane
Please Login to read the full article.
03 November 2009
Christopher Spillane
Repros Therapeutics has reached an agreement with major creditors settling a large amount of debt incurred after the firm suspended its Proellex (CDB-4124) clinical programme.
In August, the
US FDA placed INDs for Proellex on hold because of concerns that it increased liver enzyme levels,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA updates Repros on Proellex clinical hold
- Repros discontinues highest dose of Proellex in endometriosis trial
- AEterna Zentaris's lead drug fails second Phase III trial in BPH
- GENova Biotherapeutics causes concern as media blitz culminates in stock trading suspension – update
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
